论文部分内容阅读
非静脉给药的生物利用度是通过一系列消除结果(包括肠粘膜,酶,肠内细菌丛,肝及肺)来衡量化合物开始吸收的方法。本文介绍了一种理论分析方法来区别在此首次通过效应中药物的肠壁消除与肝脏排除这两个过程。方法是同时从不同途径(口服、静脉注射及腹腔注射)给药(D)或代谢物和其前体药物(P),然后测定它们的血药浓度一时间曲线下面积(简称AUC),再将所得数据代入肝脏的摄取(ER)公式(1)和肠壁消除后的总有效分数的公式(2)而求得。
The bioavailability of non-intravenous administration is a measure of the compound’s initial absorption through a series of elimination results, including intestinal mucosa, enzymes, intestinal flora, liver and lungs. This article presents a theoretical analysis to distinguish the two processes of elimination of the intestinal wall and the exclusion of the liver in the first pass of the effect. (D) or metabolites and their prodrugs (P) by different routes (oral, intravenous and intraperitoneal injection) at the same time, and then determine their area under the curve of blood concentration (AUC) The obtained data were obtained by substituting the formula (1) for the intake of the liver (1) and the total effective fraction after the intestinal wall elimination (2).